Pharmacokinetics of Mitoxantrone in Cancer Patients
Author Information
Author(s): B. Richard, M.-C. Launay-Iliadis, A. Iliadisi, S. Just-Landii, D. Blaise, A.-M. Stoppa, P. Viens, M.-H. Gaspard, D. Maraninchi, J.-P. Cano, Y. Carcassonne
Primary Institution: INSERM U278, Faculte de Pharmacie, Marseille, France
Hypothesis
Does the elimination of mitoxantrone become saturable at high doses?
Conclusion
Mitoxantrone pharmacokinetics show no saturation in elimination even at high doses, and the drug's half-life is long, necessitating careful timing before bone marrow transplantation.
Supporting Evidence
- Mitoxantrone was administered in two different regimens to study its pharmacokinetics.
- High interindividual variability in pharmacokinetic parameters was observed.
- Plasma concentrations of mitoxantrone were measured using high-performance liquid chromatography.
Takeaway
This study looked at how the body processes a cancer drug called mitoxantrone. It found that even when given in high doses, the body can still get rid of it without problems.
Methodology
The study involved two groups of cancer patients receiving different doses of mitoxantrone, with blood samples taken to analyze drug levels over time.
Potential Biases
Potential bias due to the exclusion of patients with heart disease.
Limitations
The study had a small sample size and variability in patient responses.
Participant Demographics
Fifteen women aged 16 to 63 with various types of cancer.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website